OSR Health WTS (OSRHW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OSRHW SEC filings page.
OSR Health Inc WTS (OSRHW) reported $1.8M in revenue over the twelve months to Jun 30, 2026, down 50.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains cost-heavy and cash-consuming, while 2025 improved its overall capital position but left short-term liquidity strained.
Revenue contraction coincided with a2.6 percentage-point gross-margin decline, so the lower sales base did not become more efficient. Meanwhile, selling and administrative costs rose51.4% , indicating expenses expanded against shrinking sales rather than being absorbed by growth.
Equity turned positive at
Operating cash flow was negative at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of OSR Health Inc WTS's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
OSR Health Inc WTS held $1.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $4.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and OSR Health Inc WTS scores 19/100 among other emerging companies.
OSR Health Inc WTS had 33M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and OSR Health Inc WTS scores 8/100 among other emerging companies.
OSR Health Inc WTS spent $318K on research and development in fiscal year 2025, which was 1.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and OSR Health Inc WTS scores 12/100 among other emerging companies.
OSR Health Inc WTS reported revenue of $2.9M in fiscal year 2025, against $3.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and OSR Health Inc WTS scores 22/100 among other emerging companies.
OSR Health Inc WTS's operations used $4.3M of cash in fiscal year 2025, against $1.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and OSR Health Inc WTS scores 6/100 among other emerging companies.
OSR Health Inc WTS's cash, cash equivalents and investments came to $1.7M at the end of fiscal year 2025, against $93.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and OSR Health Inc WTS scores 5/100 among other emerging companies.
OSR Health Inc WTS passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
OSR Health Inc WTS reported a net loss of $18.0M while operations used $4.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
OSR Health Inc WTS reported an operating loss of $18.3M against $506K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
OSR Health Inc WTS generated $316K in revenue in Q2 2026. This represents a decrease of 72.2% from the same quarter a year earlier. Against the prior quarter it is down 34.8%.
OSR Health Inc WTS's EBITDA was -$670K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
OSR Health Inc WTS reported a net loss of $849K in Q2 2026. This represents a decrease of 356.1% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
OSR Health Inc WTS held $1.5M in cash against $271K in long-term debt as of Q2 2026, with $15.7M of liabilities due within a year.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
OSR Health Inc WTS's gross margin was 27.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 24.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.7 percentage points.
OSR Health Inc WTS's quarterly ROE was -0.8% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for Q2 2026.
OSRHW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $316K-72.2% | $484K-36.4% | $381K-58.3% | $628K-23.7% | $1.1M+28.8% | $761K-16.4% | $915K | $823K |
| Cost of Revenue | $229K-79.2% | $324K-45.4% | $252K-66.7% | $366K-43.2% | $1.1M+69.8% | $593K-11.6% | $755K | $644K |
| Gross Profit | $87K+164.2% | $160K-5.0% | $130K-18.9% | $262K+46.1% | $33K-85.9% | $169K-29.7% | $160K | $179K |
| R&D Expenses | N/A | $113K+25.5% | $177K+1119.7% | N/A | N/A | $90K+93.0% | $14K | N/A |
| SG&A Expenses | $3.1M-40.7% | $3.8M+24.0% | $6.5M+267.5% | $4.1M+8.5% | $5.3M+52.9% | $3.1M-12.9% | $1.8M+105.7% | $3.7M+812.6% |
| Operating Income | -$3.0Mn/m | -$3.7Mn/m | -$6.4Mn/m | -$3.8Mn/m | -$5.2Mn/m | -$2.9Mn/m | -$1.6M | -$3.6M |
| EBITDA | -$670Kn/m | -$1.2Mn/m | -$4.1Mn/m | -$1.4Mn/m | -$2.9Mn/m | -$645Kn/m | -$513K | -$707K |
| Interest Expense | $13K-65.6% | $31K+90.4% | $409K+1437.3% | $44K+381.3% | $37K+1684.1% | $16K+21.1% | $27K | $9K |
| Income Tax | -$440K | -$452K | -$535Kn/m | -$1.3Mn/m | N/A | N/A | -$451K-394.4% | -$140K-207.4% |
| Net Income | -$849K-356.1% | -$2.9Mn/m | -$4.8Mn/m | -$2.1Mn/m | $331Kn/m | -$11.4Mn/m | -$2.0Mn/m | -$231K-395.4% |
| EPS (Basic) | -$0.02-200.0% | -$0.09 | -$0.16 | -$0.10 | $0.02 | -$1.04 | -$0.62 | -$1.56 |
| EPS (Diluted) | N/A | -$0.08 | -$0.23 | N/A | N/A | -$1.04 | -$0.62 | -$0.06 |
| Diluted Shares (Avg) | N/A | 34M | N/A | N/A | N/A | 11M | N/A | 4M |
OSRHW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $166.6M-10.1% | $172.2M-1.4% | $171.2M-2.3% | $177.3M+747.2% | $185.4M+798.6% | $174.6M+368.3% | $175.2M+378.4% | $20.9M-71.0% |
| Current Assets | $2.9M-0.3% | $2.9M-15.7% | $2.8M+21.1% | $3.2M+7989.8% | $2.9M+1623.4% | $3.5M+4984.8% | $2.3M+10181.9% | $40K-51.9% |
| Cash & Equivalents | $1.5M-5.4% | $1.6M-1.8% | $1.7M+397.8% | $2.2M+17694.3% | $1.6M+1230.1% | $1.6M+43774.0% | $342K+2115.1% | $12K-78.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $594K+198.9% | $462K-37.2% | $196K-78.7% | $185K | $199K | $737K | $922K | N/A |
| Accounts Receivable | $189K-74.6% | $261K-67.1% | $319K-64.7% | $489K | $743K | $795K | $904K | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $29.2M+10.6% | $29.7M+21.8% | $24.9M+2.4% | $25.5M | $26.4M | $24.4M-8.2% | $24.4M-12.3% | N/A |
| Total Liabilities | $41.7M-59.0% | $44.8M-54.7% | $93.6M-49.0% | $95.3M+257.4% | $101.7M+298.3% | $98.8M+137.6% | $183.6M+352.9% | $26.7M-64.2% |
| Current Liabilities | $15.7M-0.8% | $17.9M+28.9% | $17.2M+395.6% | $15.0M+281.4% | $15.9M+363.9% | $13.9M+405.8% | $3.5M+69.9% | $3.9M+256.6% |
| Non-Current Liabilities | $26.0M-69.7% | $26.9M-68.3% | $76.4M-57.6% | $80.3M+253.2% | $85.9M+288.2% | $84.9M+118.6% | $180.1M+367.9% | $22.7M-69.1% |
| Long-Term Debt | $271K | $273K+7.9% | N/A | $0 | N/A | $253K | $498K | N/A |
| Total Equity | $104.3M+24.6% | $103.9M+37.1% | $77.6Mn/m | $81.9Mn/m | $83.7Mn/m | $75.8Mn/m | -$8.3Mn/m | -$5.8Mn/m |
| Retained Earnings | -$41.0Mn/m | -$40.1Mn/m | -$37.2Mn/m | -$32.3Mn/m | -$30.2Mn/m | -$30.6Mn/m | -$19.2Mn/m | -$5.8Mn/m |
OSRHW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.4Mn/m | -$1.0Mn/m | -$1.1Mn/m | -$2.7Mn/m | -$483Kn/m | -$64Kn/m | -$181Kn/m | -$686Kn/m |
| Depreciation & Amortization | $2.4M+0.5% | $2.4M+6.7% | $2.3M+108.5% | $2.4M-16.5% | $2.4M-14.9% | $2.3M-22.0% | $1.1M | $2.9M |
| Investing Cash Flow | -$88Kn/m | $12K-99.0% | -$2.6Mn/m | -$727K-396.3% | -$528K-340.7% | $1.2M+423.1% | -$188K-100.5% | $245Kn/m |
| Financing Cash Flow | $2.5M+177.4% | $942K+530.7% | $3.2M+898.9% | $4.1M+1117.8% | $891K+245.2% | $149K-44.0% | $322Kn/m | $338K+69.0% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $19.2M-46.7% | $0n/m |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid.
OSRHW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 27.4%+24.5pp | 33.1%+11.0pp | 34.0%+16.5pp | 41.7%+19.9pp | 2.9%-23.5pp | 22.2%-4.2pp | 17.5% | 21.8% |
| Operating Margin | -960.8% | -757.6% | -1674.8% | -605.9% | -460.5% | -383.3% | -176.2% | -433.4% |
| Net Margin | -268.9% | -605.6% | -1265.0% | -338.8% | 29.2%+40.2pp | -1496.6% | -220.9% | -28.1% |
| Return on Equity | -0.8%-1.2pp | -2.8%+12.2pp | -6.2% | -2.6% | 0.4% | -15.0% | N/A | N/A |
| Return on Assets | -0.5%-0.7pp | -1.7%+4.8pp | -2.8%-1.7pp | -1.2%-0.1pp | 0.2%+0.7pp | -6.5%-6.4pp | -1.1%-0.9pp | -1.1%-1.2pp |
| Current Ratio | 0.180.0x | 0.16-0.1x | 0.16-0.5x | 0.21+0.2x | 0.18+0.1x | 0.25+0.2x | 0.67+0.7x | 0.01-0.1x |
| Debt-to-Equity | 0.00 | 0.000.0x | N/A | 0.00 | N/A | 0.00 | N/A | N/A |
| Liabilities-to-Equity | 0.40-0.8x | 0.43-0.9x | 1.21 | 1.16 | 1.22 | 1.30 | N/A | N/A |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.000.0x | 0.01 | 0.04 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OSR Health Inc WTS OSRHW | FY2025 | $2.9M | -$18.0M | N/A | N/A | 12/100 |
| Stellar V Capital Corp. SVCC | FY2025 | N/A | $5.3M | N/A | $242.2M | — |
| Fortrea Holdings Inc. FTRE | FY2025 | $2.7B | -$986.2M | -36.2% | $2.0B | 24/100 |
| Aldel Financial II Inc. ALDF | FY2025 | N/A | $9.2M | N/A | $321.1M | — |
Where OSR Health Inc WTS Ranks
Frequently Asked Questions
OSR Health Inc WTS (OSRHW) reported $2.9M in total revenue for fiscal year 2025. This represents a -17.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
OSR Health Inc WTS (OSRHW) revenue declined by 17.7% year-over-year, from $3.5M to $2.9M in fiscal year 2025.
No, OSR Health Inc WTS (OSRHW) reported a net loss of $10.7M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $18.0M.
OSR Health Inc WTS (OSRHW) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
OSR Health Inc WTS (OSRHW) had a gross margin of 20.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
OSR Health Inc WTS (OSRHW) has a return on equity of -23.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
OSR Health Inc WTS (OSRHW) recorded an outflow of $4.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
OSR Health Inc WTS (OSRHW) had $171.2M in total assets as of fiscal year 2025, including both current and long-term assets.
OSR Health Inc WTS (OSRHW) invested $318K in research and development during fiscal year 2025.
OSR Health Inc WTS (OSRHW) had a current ratio of 0.16 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
OSR Health Inc WTS (OSRHW) had a liabilities-to-equity ratio of 1.21 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
OSR Health Inc WTS (OSRHW) had a return on assets of -10.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, OSR Health Inc WTS (OSRHW) held $1.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.3M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
OSR Health Inc WTS (OSRHW) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
OSR Health Inc WTS (OSRHW) reported a net loss of $18.0M while operations used $4.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
OSR Health Inc WTS (OSRHW) reported an operating loss of $18.3M against $506K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
OSR Health Inc WTS (OSRHW) scores 12 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.